Anti-Tau antibodies and methods of use thereof

US11370832B2 · kind B2 · utility

Assignee

• DENALI THERAPEUTICS INC. · US

Inventors

• Xiaocheng Chen · Foster City, US
• Mark S. Dennis · South San Francisco, US
• Lesley Ann Kane · South San Francisco, US
• Do Jin Kim · South San Francisco, US
• Joseph Wesley LEWCOCK · Redwood City, US
• Suresh Poda · South San Francisco, US
• Rishi Rakhit · Toronto, CA
• Rinkan Shukla · South San Francisco, US
• Adam P. Silverman · South San Francisco, US

Key dates

• Filing date: Aug 16, 2019
• Grant date: Jun 28, 2022
• Expiry date: Aug 16, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

In one aspect, antibodies that specifically bind to a human Tau protein are provided. In some embodiments, an anti-Tau antibody recognizes an epitope within residues 111-125 of full-length human Tau, an epitope within residues 251-270 and/or residues 346-360 of full-length human Tau, or an epitope within residues 186-205 of full-length human Tau. In some embodiments, an anti-Tau antibody specifically binds to phosphorylated human Tau, unphosphorylated human Tau, and/or multiple splice isoforms of human Tau. An anti-Tau antibody disclosed herein may also include one or two modified Fc polypeptides.